BR112023000501A2 - Partículas de lapatinibe e usos das mesmas - Google Patents

Partículas de lapatinibe e usos das mesmas

Info

Publication number
BR112023000501A2
BR112023000501A2 BR112023000501A BR112023000501A BR112023000501A2 BR 112023000501 A2 BR112023000501 A2 BR 112023000501A2 BR 112023000501 A BR112023000501 A BR 112023000501A BR 112023000501 A BR112023000501 A BR 112023000501A BR 112023000501 A2 BR112023000501 A2 BR 112023000501A2
Authority
BR
Brazil
Prior art keywords
particles
lapatinib
ssa
volume
pharmaceutically acceptable
Prior art date
Application number
BR112023000501A
Other languages
English (en)
Inventor
Sittenauer Jacob
Farthing Joseph
Williams Mark
Baltezor Michael
Dizerega Gere
Barreda Abarca Aranza
Clark Shelby
Original Assignee
Crititech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crititech Inc filed Critical Crititech Inc
Publication of BR112023000501A2 publication Critical patent/BR112023000501A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PARTÍCULAS DE LAPATINIBE E USOS DAS MESMAS. Esta descrição prevê partículas de pelo menos 95% em peso de lapatinibe, ou um sal farmaceuticamente aceitável do mesmo, em que as partículas têm uma área superficial específica (SSA) de pelo menos 10 m2/g e têm um tamanho de partícula médio em distribuição de volume entre cerca de 0,7 µm e cerca de 8 µm.
BR112023000501A 2020-07-23 2021-07-21 Partículas de lapatinibe e usos das mesmas BR112023000501A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063055788P 2020-07-23 2020-07-23
PCT/US2021/042554 WO2022020455A1 (en) 2020-07-23 2021-07-21 Lapatinib particles and uses thereof

Publications (1)

Publication Number Publication Date
BR112023000501A2 true BR112023000501A2 (pt) 2023-01-31

Family

ID=77338850

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000501A BR112023000501A2 (pt) 2020-07-23 2021-07-21 Partículas de lapatinibe e usos das mesmas

Country Status (9)

Country Link
US (1) US20220023215A1 (pt)
EP (1) EP4185294A1 (pt)
JP (1) JP2023535390A (pt)
KR (1) KR20230044423A (pt)
CN (1) CN115720519A (pt)
AU (1) AU2021314153A1 (pt)
BR (1) BR112023000501A2 (pt)
CA (1) CA3183494A1 (pt)
WO (1) WO2022020455A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086779A1 (en) 2021-11-10 2023-05-19 Crititech, Inc. Niraparib particles and uses thereof
WO2023086784A1 (en) 2021-11-10 2023-05-19 Crititech, Inc. Rucaparib particles and uses thereof
CN116139081B (zh) * 2023-03-14 2023-12-22 浙江省肿瘤医院 一种口服拉帕替尼混悬剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US20110071169A1 (en) * 2009-08-26 2011-03-24 Mai De Ltd Preparation of polymorphic form of lapatinib ditosylate
EP2802314B1 (en) * 2012-01-13 2020-11-25 XSpray Microparticles AB A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
WO2015145145A1 (en) * 2014-03-24 2015-10-01 Cipla Limited Pharmaceutical composition comprising lapatinib
JP6921759B2 (ja) 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド 捕集装置および使用法
CA3076919A1 (en) * 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer

Also Published As

Publication number Publication date
US20220023215A1 (en) 2022-01-27
EP4185294A1 (en) 2023-05-31
KR20230044423A (ko) 2023-04-04
JP2023535390A (ja) 2023-08-17
WO2022020455A1 (en) 2022-01-27
CA3183494A1 (en) 2022-01-27
US20220370355A1 (en) 2022-11-24
AU2021314153A1 (en) 2023-01-05
CN115720519A (zh) 2023-02-28

Similar Documents

Publication Publication Date Title
BR112023000501A2 (pt) Partículas de lapatinibe e usos das mesmas
BRPI0508077A (pt) produto de suspensão para reduzir umidade embaixo do braço
BR112023000500A2 (pt) Partículas de sorafenibe e usos das mesmas
BRPI0607298A2 (pt) artigos abrasivos e processos para obtenção dos mesmos
BR112017020767A2 (pt) artigo abrasivo revestido e método para fabricação do mesmo
BR0309148A (pt) Composição de revestimento, método para transmitir resistência à abrasão a assoalhos e a um substrato, e, assoalho de madeira ou de vinilo
MX356779B (es) Composicion que comprende un agente de control biologico y un fungicida.
BR0204406A (pt) Revestimento, partìcula compósita, composição de revestimento, processo para preparar uma partìcula compósita, dispersão aquosa, dispersão de partìculas compósitas, processos para formar partìculas compósitas, e para preparar uma dispersão aquosa, e, composição aquosa
Sapuntsova et al. Status of free-radical oxidation and proliferation processes in patients with atopic dermatitis and lichen planus
BR112018069402A2 (pt) chapa de aço resistente à abrasão e método para produzir chapa de aço resistente à abrasão
BR112018013724A2 (pt) materiais de construção de compósito particulado
BR112019000306A2 (pt) chapa de aço e chapa de aço galvanizada
BR112017015008A2 (pt) trilho
BRPI0614080A2 (pt) Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporose
BR112018068812A2 (pt) método para a produção de água potável
BR112018072768A2 (pt) suspensão, composição farmacêutica, método para formar uma suspensão fulvestrant aquosa, suspensão fulvestrant aquosa e método para tratar um indivíduo tendo câncer de mama
WO2021028844A3 (en) System and method for assessing the risk of schizophrenia
Steadman et al. Type 1 fimbriate Escherichia coli stimulates a unique pattern of degranulation by human polymorphonuclear leukocytes
PL1860948T3 (pl) Sposób usuwania pasożytów i proszek pasożytobójczy
Durie et al. Determining the incidence of interstitial pneumonitis and chronic kidney disease following full intensity haemopoetic stem cell transplant conditioned using a forward-planned intensity modulated total body irradiation technique
BR0314117A (pt) Uso tópico de alumina calcinada microfina
BR112015020061A8 (pt) composto alvo anidrase carbônica ix (caix) para tratamento de câncer, seus usos, composição farmcêutica, e método para diagnosticar, prognosticar e/ou classificar um câncer
BR112018005857A2 (pt) composição para cuidados com a pele, e, métodos para proteger pele de danos por uva e uvb e para aumentar a absorção de spf ou uv.
BRPI0407548A (pt) composições compreendendo um componente polissacarìdeo e uma ou mais camadas de revestimento
BRPI0402499A (pt) Armação lateral e método para reparar ou manter uma armação lateral para um conjunto roda-truque de vagão ferroviário que suporta um vagão ferroviário